AAO: Higher-Dose Injection No Better for Retinal Vein Occlusion
Increasing the dose of intravitreal bevacizumab (Avastin) doesn't improve outcomes for central retinal vein occlusion, according to research presented at the recent annual AAO conference.
» Click here to register.

Inflammation May Predict Corneal Rejection
Subclinical inflammation in the eyes of patients with herpes simplex virus keratitis may predict the rejection of corneal transplants, a retrospective study shows.
» Click here to register.

You are subscribed to ModernMedicine.com. To unsubscribe, click here

To ensure delivery to your Inbox, please add us to your address book. If you need help doing this, click here.

Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 1-866-529-2922 at any time, or fax us at 1-218-740-6417. Outside the U.S., please phone 1-218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.